Barclays Raises Teva Pharmaceutical (TEVA) PT to $38 Following Strong Q4 Earnings Beat [Yahoo! Finance]
Teva Pharmaceutical Industries Limited American Depositary Shares (TEVA)
Last teva pharmaceutical industries limited american depositary shares earnings: 2/13 04:01 pm
Check Earnings Report
US:NYSE Investor Relations:
ir.tevapharm.com
Company Research
Source: Yahoo! Finance
On January 30, Barclays analyst Glen Santangelo raised the price target for Teva Pharmaceuticals to $38 from $35 with an Overweight rating. Following Teva Pharmaceuticals' Q4 2025 report, the firm updated its financial model and expressed continued confidence in the stock's current valuation. A day before that, Scotiabank raised the price target on Teva Pharmaceuticals to $40 from $35 while maintaining an Outperform rating. The firm is positive on the stock following Q4 2025 results and noted that the company's execution continues to exceed expectations. In other news, on January 14, Teva Pharmaceutical Industries Limited (NYSE:TEVA) announced that the New England Journal of Medicine published Phase 3 data from the SPACE trial, confirming that AJOVY (fremanezumab-vfrm) significantly reduces monthly migraine and headache days in children and adolescents (ages 6–17). Following its August 2025 FDA approval for pediatric patients weighing 45 kg or more, AJOVY is now the first and only
Show less
Read more
Impact Snapshot
Event Time:
TEVA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TEVA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TEVA alerts
High impacting Teva Pharmaceutical Industries Limited American Depositary Shares news events
Weekly update
A roundup of the hottest topics
TEVA
News
- Teva Pharmaceutical Industries Limited (TEVA): A Bull Case Theory [Yahoo! Finance]Yahoo! Finance
- Jim Cramer Highlights Teva Pharmaceutical's Growth Under CEO Richard Francis [Yahoo! Finance]Yahoo! Finance
- Analysts See Pipeline Catalysts Driving Teva Pharmaceutical Industries Limited (TEVA)'s 2026 Growth Despite Revenue Headwinds [Yahoo! Finance]Yahoo! Finance
- Teva Pharmaceutical Industries (NYSE:TEVA) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=TEVA&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">WMarketBeat
- Does Teva's Return To Profitability And Branded-Drug Shift Reshape The Bull Case For TEVA? [Yahoo! Finance]Yahoo! Finance
TEVA
Earnings
- 1/28/26 - Beat
TEVA
Sec Filings
- 2/3/26 - Form 10-K
- 1/29/26 - Form 4
- 1/29/26 - Form 4
- TEVA's page on the SEC website